It has been shown that Listeria monocytogenes (Lm)-based vaccine targeting RGS5 exhibits potent anti-tumor effects by recruiting functional type-1-associated T cells and reducing tumor blood vessel rates in syngeneic mouse models of CRC. The gene discussed is RGS5; the disease is colorectal carcinoma.